<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956097</url>
  </required_header>
  <id_info>
    <org_study_id>HX106</org_study_id>
    <nct_id>NCT01956097</nct_id>
  </id_info>
  <brief_title>Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function</brief_title>
  <official_title>Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the current study are to evaluate the efficacy and safety of HX106 in
      healthy adults with subjective memory complaints for improving neurocognitive functions and
      to find the changes of brain using magnetic resonance imaging and their associations with the
      neurocognitive function enhancement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Working Memory Domain Z-score</measure>
    <time_frame>Baseline, 8th week</time_frame>
    <description>To assess the working memory performance, four well-established tests, including the symbol span from the Wechsler Memory Scale-IV, immediate recall domain from the Rey-Osterrieth Complex Figure Test, digit span, and letter number sequencing from the Korean version of the Wechsler Adult Intelligence Scale were chosen.
Each test score was adjusted with age, sex, intelligent quotient, years of education, and baseline test scores. The adjusted test scores were then standardized into z-scores using all participants' means and standard deviations. The relative improvement (positive z-scores) or decline (negative z-scores) in performance was measured in a unit-free manner using the obtained z-scores. The individual z-scores of each test were averaged to the composite score for working memory domain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in White Matter Integrity Assessment</measure>
    <time_frame>Baseline, 8th weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>1st week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>4th weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>8th weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy Adults With Subjective Memory Complaints</condition>
  <arm_group>
    <arm_group_label>HX106 590mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HX106 590mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HX106 1180mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HX106 1180mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HX106 590mg</intervention_name>
    <arm_group_label>HX106 590mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HX106 1180mg</intervention_name>
    <arm_group_label>HX106 1180mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 60 years old,

          -  Global Deterioration Scale score (GDS) of 2

          -  One or more symptoms of subjective memory impairment

          -  High school or higher levels of education.

        Exclusion Criteria:

          -  Current pregnancy or breast-feeding

          -  Evidence of neurologic or medical conditions

          -  Axis I diagnosis when assessed by the board certified psychiatrist using the
             Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental
             Disorder, 4th edition (DSM-IV)(SCID-IV),

          -  One or more major depressive episode during last 12 months

          -  Mini-mental status examination score of 24 or less

          -  Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond
             self-perceived subjective deficits

          -  Intelligence quotient less than 80

          -  Any history of head trauma involving loss of consciousness or seizure

          -  Contraindications to magnetic resonance imaging (MRI)

          -  Use of psychotropics in last 3 months

          -  Use of oral contraceptive medication

          -  Participation in other clinical trials during the study period that might affect the
             outcome of the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha W. University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ewha W. University</name>
      <address>
        <city>Seoul</city>
        <zip>120-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>May 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2015</results_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HX106 590mg</title>
          <description>HX106 590mg/day
HX106 590mg</description>
        </group>
        <group group_id="P2">
          <title>HX106 1180mg</title>
          <description>HX106 1180mg/day
HX106 1180mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HX106 590mg</title>
          <description>HX106 590mg/day
HX106 590mg</description>
        </group>
        <group group_id="B2">
          <title>HX106 1180mg</title>
          <description>HX106 1180mg/day
HX106 1180mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="11.7"/>
                    <measurement group_id="B2" value="42.5" spread="11.2"/>
                    <measurement group_id="B3" value="40.6" spread="12.7"/>
                    <measurement group_id="B4" value="40.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Working Memory Domain Z-score</title>
        <description>To assess the working memory performance, four well-established tests, including the symbol span from the Wechsler Memory Scale-IV, immediate recall domain from the Rey-Osterrieth Complex Figure Test, digit span, and letter number sequencing from the Korean version of the Wechsler Adult Intelligence Scale were chosen.
Each test score was adjusted with age, sex, intelligent quotient, years of education, and baseline test scores. The adjusted test scores were then standardized into z-scores using all participants' means and standard deviations. The relative improvement (positive z-scores) or decline (negative z-scores) in performance was measured in a unit-free manner using the obtained z-scores. The individual z-scores of each test were averaged to the composite score for working memory domain.</description>
        <time_frame>Baseline, 8th week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HX106 590mg</title>
            <description>HX106 590mg/day
HX106 590mg</description>
          </group>
          <group group_id="O2">
            <title>HX106 1180mg</title>
            <description>HX106 1180mg/day
HX106 1180mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Working Memory Domain Z-score</title>
          <description>To assess the working memory performance, four well-established tests, including the symbol span from the Wechsler Memory Scale-IV, immediate recall domain from the Rey-Osterrieth Complex Figure Test, digit span, and letter number sequencing from the Korean version of the Wechsler Adult Intelligence Scale were chosen.
Each test score was adjusted with age, sex, intelligent quotient, years of education, and baseline test scores. The adjusted test scores were then standardized into z-scores using all participants' means and standard deviations. The relative improvement (positive z-scores) or decline (negative z-scores) in performance was measured in a unit-free manner using the obtained z-scores. The individual z-scores of each test were averaged to the composite score for working memory domain.</description>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21955" spread="0.04450"/>
                    <measurement group_id="O2" value="-0.15432" spread="0.03883"/>
                    <measurement group_id="O3" value="-0.08842" spread="0.06861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29594" spread="0.16938"/>
                    <measurement group_id="O2" value="0.34061" spread="0.13436"/>
                    <measurement group_id="O3" value="-0.27524" spread="0.13489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in White Matter Integrity Assessment</title>
        <time_frame>Baseline, 8th weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>1st week</time_frame>
        <population>2 participants in the &quot;HX106 590mg&quot; group and 1 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
        <group_list>
          <group group_id="O1">
            <title>HX106 590mg</title>
            <description>HX106 590mg/day
HX106 590mg</description>
          </group>
          <group group_id="O2">
            <title>HX106 1180mg</title>
            <description>HX106 1180mg/day
HX106 1180mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>2 participants in the &quot;HX106 590mg&quot; group and 1 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>4th weeks</time_frame>
        <population>3 participants in the &quot;HX106 590mg&quot; group and 1 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
        <group_list>
          <group group_id="O1">
            <title>HX106 590mg</title>
            <description>HX106 590mg/day
HX106 590mg</description>
          </group>
          <group group_id="O2">
            <title>HX106 1180mg</title>
            <description>HX106 1180mg/day
HX106 1180mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>3 participants in the &quot;HX106 590mg&quot; group and 1 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>8th weeks</time_frame>
        <population>6 participants in the &quot;HX106 590mg&quot; group and 2 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
        <group_list>
          <group group_id="O1">
            <title>HX106 590mg</title>
            <description>HX106 590mg/day
HX106 590mg</description>
          </group>
          <group group_id="O2">
            <title>HX106 1180mg</title>
            <description>HX106 1180mg/day
HX106 1180mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>6 participants in the &quot;HX106 590mg&quot; group and 2 participant in the &quot;HX106 1180mg&quot; were dropped out.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HX106 590mg</title>
          <description>HX106 590mg/day
HX106 590mg</description>
        </group>
        <group group_id="E2">
          <title>HX106 1180mg</title>
          <description>HX106 1180mg/day
HX106 1180mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic symptoms: palpitations/tachycardia</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic symptoms: accomodation disturbances</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic symptoms: diarrhea</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: constipation</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: nausea/vomitting</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other symptoms: weight gain</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other symptoms: weight loss</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other symptoms: headache</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: orthostatic dizziness</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: increased tendency to sweating</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: reduced salivation</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic symptoms: dystonia</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neurologic symptoms: rigidity</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neurologic symptoms: paresthesia</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychic symptoms: increased fatigability</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: sleepiness/sedation</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: failing memory</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: depression</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: tension/inner unrest</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: increased duration of sleep</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: reduced duration of sleep</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychic symptoms: increased dream activity</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic symptoms: micturition disturbances</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Autonomic symptoms: polyuria/polydipsia</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Other symptoms: increased sexual desire</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other symptoms: rash</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other symptoms: morbilliform</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other symptoms: cannot be classified</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other symptoms: pruritus</sub_title>
                <description>any of the side effects listed in the UKU side effect rating scale</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Soonhyun Ban, RN, MS</name_or_title>
      <organization>Ewha Brain Institute, Ewha W. University</organization>
      <phone>+82-2-3277-6550 ext 6554</phone>
      <email>soonhyun.s.ban@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

